#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia Several models have been proposed to account for observed overlaps in clinical features and genetic predisposition between schizophrenia and autism spectrum disorder.
1-1	0-8	Positron	_
1-2	9-17	emission	_
1-3	18-28	tomography	_
1-4	29-39	assessment	_
1-5	40-42	of	_
1-6	43-51	cerebral	_
1-7	52-59	glucose	_
1-8	60-69	metabolic	_
1-9	70-75	rates	_
1-10	76-78	in	_
1-11	79-85	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-12	86-94	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-13	95-103	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-14	104-107	and	_
1-15	108-121	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	122-129	Several	_
1-17	130-136	models	_
1-18	137-141	have	_
1-19	142-146	been	_
1-20	147-155	proposed	_
1-21	156-158	to	_
1-22	159-166	account	_
1-23	167-170	for	_
1-24	171-179	observed	_
1-25	180-188	overlaps	_
1-26	189-191	in	_
1-27	192-200	clinical	_
1-28	201-209	features	_
1-29	210-213	and	_
1-30	214-221	genetic	_
1-31	222-236	predisposition	_
1-32	237-244	between	_
1-33	245-258	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-34	259-262	and	_
1-35	263-269	autism	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-36	270-278	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-37	279-287	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-38	288-289	.	_

Text=This study assessed similarities and differences in topological patterns and vectors of glucose metabolism in both disorders in reference to these models.
2-1	290-294	This	_
2-2	295-300	study	_
2-3	301-309	assessed	_
2-4	310-322	similarities	_
2-5	323-326	and	_
2-6	327-338	differences	_
2-7	339-341	in	_
2-8	342-353	topological	_
2-9	354-362	patterns	_
2-10	363-366	and	_
2-11	367-374	vectors	_
2-12	375-377	of	_
2-13	378-385	glucose	_
2-14	386-396	metabolism	_
2-15	397-399	in	_
2-16	400-404	both	_
2-17	405-414	disorders	_
2-18	415-417	in	_
2-19	418-427	reference	_
2-20	428-430	to	_
2-21	431-436	these	_
2-22	437-443	models	_
2-23	444-445	.	_

Text=Co-registered 18F-FDG PET and MRI scans were obtained in 41 schizophrenia, 25 ASD, and 55 healthy control subjects.
3-1	446-459	Co-registered	_
3-2	460-467	18F-FDG	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
3-3	468-471	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
3-4	472-475	and	_
3-5	476-479	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
3-6	480-485	scans	_
3-7	486-490	were	_
3-8	491-499	obtained	_
3-9	500-502	in	_
3-10	503-505	41	_
3-11	506-519	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-12	520-521	,	_
3-13	522-524	25	_
3-14	525-528	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-15	529-530	,	_
3-16	531-534	and	_
3-17	535-537	55	_
3-18	538-545	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-19	546-553	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-20	554-562	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-21	563-564	.	_

Text=AFNI was used to map cortical and subcortical regions of interest.
4-1	565-569	AFNI	_
4-2	570-573	was	_
4-3	574-578	used	_
4-4	579-581	to	_
4-5	582-585	map	_
4-6	586-594	cortical	_
4-7	595-598	and	_
4-8	599-610	subcortical	_
4-9	611-618	regions	_
4-10	619-621	of	_
4-11	622-630	interest	_
4-12	631-632	.	_

Text=Metabolic rates were compared between three diagnostic groups using univariate and multivariate repeated-measures ANOVA.
5-1	633-642	Metabolic	_
5-2	643-648	rates	_
5-3	649-653	were	_
5-4	654-662	compared	_
5-5	663-670	between	_
5-6	671-676	three	_
5-7	677-687	diagnostic	_
5-8	688-694	groups	_
5-9	695-700	using	_
5-10	701-711	univariate	_
5-11	712-715	and	_
5-12	716-728	multivariate	_
5-13	729-746	repeated-measures	_
5-14	747-752	ANOVA	_
5-15	753-754	.	_

Text=Compared to controls, metabolic rates in schizophrenia subjects were decreased in the frontal lobe, anterior cingulate, superior temporal gyrus, amygdala and medial thalamic nuclei; rates were increased in the occipital cortex, hippocampus, basal ganglia and lateral thalamic nuclei.
6-1	755-763	Compared	_
6-2	764-766	to	_
6-3	767-775	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-4	776-777	,	_
6-5	778-787	metabolic	_
6-6	788-793	rates	_
6-7	794-796	in	_
6-8	797-810	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-9	811-819	subjects	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-10	820-824	were	_
6-11	825-834	decreased	_
6-12	835-837	in	_
6-13	838-841	the	_
6-14	842-849	frontal	_
6-15	850-854	lobe	_
6-16	855-856	,	_
6-17	857-865	anterior	_
6-18	866-875	cingulate	_
6-19	876-877	,	_
6-20	878-886	superior	_
6-21	887-895	temporal	_
6-22	896-901	gyrus	_
6-23	902-903	,	_
6-24	904-912	amygdala	_
6-25	913-916	and	_
6-26	917-923	medial	_
6-27	924-932	thalamic	_
6-28	933-939	nuclei	_
6-29	940-941	;	_
6-30	942-947	rates	_
6-31	948-952	were	_
6-32	953-962	increased	_
6-33	963-965	in	_
6-34	966-969	the	_
6-35	970-979	occipital	_
6-36	980-986	cortex	_
6-37	987-988	,	_
6-38	989-1000	hippocampus	_
6-39	1001-1002	,	_
6-40	1003-1008	basal	_
6-41	1009-1016	ganglia	_
6-42	1017-1020	and	_
6-43	1021-1028	lateral	_
6-44	1029-1037	thalamic	_
6-45	1038-1044	nuclei	_
6-46	1045-1046	.	_

Text=In ASD subjects metabolic rates were decreased in the parietal lobe, frontal premotor and eye-fields areas, and amygdala; rates were increased in the posterior cingulate, occipital cortex, hippocampus and basal ganglia.
7-1	1047-1049	In	_
7-2	1050-1053	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-3	1054-1062	subjects	_
7-4	1063-1072	metabolic	_
7-5	1073-1078	rates	_
7-6	1079-1083	were	_
7-7	1084-1093	decreased	_
7-8	1094-1096	in	_
7-9	1097-1100	the	_
7-10	1101-1109	parietal	_
7-11	1110-1114	lobe	_
7-12	1115-1116	,	_
7-13	1117-1124	frontal	_
7-14	1125-1133	premotor	_
7-15	1134-1137	and	_
7-16	1138-1148	eye-fields	_
7-17	1149-1154	areas	_
7-18	1155-1156	,	_
7-19	1157-1160	and	_
7-20	1161-1169	amygdala	_
7-21	1170-1171	;	_
7-22	1172-1177	rates	_
7-23	1178-1182	were	_
7-24	1183-1192	increased	_
7-25	1193-1195	in	_
7-26	1196-1199	the	_
7-27	1200-1209	posterior	_
7-28	1210-1219	cingulate	_
7-29	1220-1221	,	_
7-30	1222-1231	occipital	_
7-31	1232-1238	cortex	_
7-32	1239-1240	,	_
7-33	1241-1252	hippocampus	_
7-34	1253-1256	and	_
7-35	1257-1262	basal	_
7-36	1263-1270	ganglia	_
7-37	1271-1272	.	_

Text=In relation to controls, subjects with ASD and schizophrenia showed opposite changes in metabolic rates in the primary motor and somatosensory cortex, anterior cingulate and hypothalamus; similar changes were found in prefrontal and occipital cortices, inferior parietal lobule, amygdala, hippocampus, and basal ganglia.
8-1	1273-1275	In	_
8-2	1276-1284	relation	_
8-3	1285-1287	to	_
8-4	1288-1296	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-5	1297-1298	,	_
8-6	1299-1307	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-7	1308-1312	with	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-8	1313-1316	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
8-9	1317-1320	and	_
8-10	1321-1334	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-11	1335-1341	showed	_
8-12	1342-1350	opposite	_
8-13	1351-1358	changes	_
8-14	1359-1361	in	_
8-15	1362-1371	metabolic	_
8-16	1372-1377	rates	_
8-17	1378-1380	in	_
8-18	1381-1384	the	_
8-19	1385-1392	primary	_
8-20	1393-1398	motor	_
8-21	1399-1402	and	_
8-22	1403-1416	somatosensory	_
8-23	1417-1423	cortex	_
8-24	1424-1425	,	_
8-25	1426-1434	anterior	_
8-26	1435-1444	cingulate	_
8-27	1445-1448	and	_
8-28	1449-1461	hypothalamus	_
8-29	1462-1463	;	_
8-30	1464-1471	similar	_
8-31	1472-1479	changes	_
8-32	1480-1484	were	_
8-33	1485-1490	found	_
8-34	1491-1493	in	_
8-35	1494-1504	prefrontal	_
8-36	1505-1508	and	_
8-37	1509-1518	occipital	_
8-38	1519-1527	cortices	_
8-39	1528-1529	,	_
8-40	1530-1538	inferior	_
8-41	1539-1547	parietal	_
8-42	1548-1554	lobule	_
8-43	1555-1556	,	_
8-44	1557-1565	amygdala	_
8-45	1566-1567	,	_
8-46	1568-1579	hippocampus	_
8-47	1580-1581	,	_
8-48	1582-1585	and	_
8-49	1586-1591	basal	_
8-50	1592-1599	ganglia	_
8-51	1600-1601	.	_

Text=Schizophrenia and ASD appear to be associated with a similar pattern of metabolic abnormalities in the social brain.
9-1	1602-1615	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-2	1616-1619	and	_
9-3	1620-1623	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-4	1624-1630	appear	_
9-5	1631-1633	to	_
9-6	1634-1636	be	_
9-7	1637-1647	associated	_
9-8	1648-1652	with	_
9-9	1653-1654	a	_
9-10	1655-1662	similar	_
9-11	1663-1670	pattern	_
9-12	1671-1673	of	_
9-13	1674-1683	metabolic	_
9-14	1684-1697	abnormalities	_
9-15	1698-1700	in	_
9-16	1701-1704	the	_
9-17	1705-1711	social	_
9-18	1712-1717	brain	_
9-19	1718-1719	.	_

Text=Divergent maladaptive trade-offs, as postulated by the diametrical hypothesis of their evolutionary relationship, may involve a more circumscribed set of anterior cingulate, motor and somatosensory regions and the specific cognitive functions they subserve.
10-1	1720-1729	Divergent	_
10-2	1730-1741	maladaptive	_
10-3	1742-1752	trade-offs	_
10-4	1753-1754	,	_
10-5	1755-1757	as	_
10-6	1758-1768	postulated	_
10-7	1769-1771	by	_
10-8	1772-1775	the	_
10-9	1776-1787	diametrical	_
10-10	1788-1798	hypothesis	_
10-11	1799-1801	of	_
10-12	1802-1807	their	_
10-13	1808-1820	evolutionary	_
10-14	1821-1833	relationship	_
10-15	1834-1835	,	_
10-16	1836-1839	may	_
10-17	1840-1847	involve	_
10-18	1848-1849	a	_
10-19	1850-1854	more	_
10-20	1855-1868	circumscribed	_
10-21	1869-1872	set	_
10-22	1873-1875	of	_
10-23	1876-1884	anterior	_
10-24	1885-1894	cingulate	_
10-25	1895-1896	,	_
10-26	1897-1902	motor	_
10-27	1903-1906	and	_
10-28	1907-1920	somatosensory	_
10-29	1921-1928	regions	_
10-30	1929-1932	and	_
10-31	1933-1936	the	_
10-32	1937-1945	specific	_
10-33	1946-1955	cognitive	_
10-34	1956-1965	functions	_
10-35	1966-1970	they	_
10-36	1971-1979	subserve	_
10-37	1980-1981	.	_

Text=Methods Participants Study participants comprised 41 subjects with schizophrenia (age=40.0±18.0 years, 9 females), 25 subjects with ASD (age=31.48±11.57, 4 females), and 55 healthy controls (age=33.36±12.85, 26 females).
11-1	1982-1989	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1990-2002	Participants	_
11-3	2003-2008	Study	_
11-4	2009-2021	participants	_
11-5	2022-2031	comprised	_
11-6	2032-2034	41	_
11-7	2035-2043	subjects	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-8	2044-2048	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-9	2049-2062	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-10	2063-2064	(	_
11-11	2065-2078	age=40.0±18.0	_
11-12	2079-2084	years	_
11-13	2085-2086	,	_
11-14	2087-2088	9	_
11-15	2089-2096	females	_
11-16	2097-2098	)	_
11-17	2099-2100	,	_
11-18	2101-2103	25	_
11-19	2104-2112	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-20	2113-2117	with	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-21	2118-2121	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-22	2122-2123	(	_
11-23	2124-2139	age=31.48±11.57	_
11-24	2140-2141	,	_
11-25	2142-2143	4	_
11-26	2144-2151	females	_
11-27	2152-2153	)	_
11-28	2154-2155	,	_
11-29	2156-2159	and	_
11-30	2160-2162	55	_
11-31	2163-2170	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-32	2171-2179	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-33	2180-2181	(	_
11-34	2182-2197	age=33.36±12.85	_
11-35	2198-2199	,	_
11-36	2200-2202	26	_
11-37	2203-2210	females	_
11-38	2211-2212	)	_
11-39	2213-2214	.	_

Text=Subjects with schizophrenia were recruited from the inpatient and outpatient services at Pilgrim State Psychiatric Center, Mount Sinai Hospital and the Bronx VA Medical Center in the New York metropolitan area.
12-1	2215-2223	Subjects	_
12-2	2224-2228	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-3	2229-2242	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-4	2243-2247	were	_
12-5	2248-2257	recruited	_
12-6	2258-2262	from	_
12-7	2263-2266	the	_
12-8	2267-2276	inpatient	_
12-9	2277-2280	and	_
12-10	2281-2291	outpatient	_
12-11	2292-2300	services	_
12-12	2301-2303	at	_
12-13	2304-2311	Pilgrim	_
12-14	2312-2317	State	_
12-15	2318-2329	Psychiatric	_
12-16	2330-2336	Center	_
12-17	2337-2338	,	_
12-18	2339-2344	Mount	_
12-19	2345-2350	Sinai	_
12-20	2351-2359	Hospital	_
12-21	2360-2363	and	_
12-22	2364-2367	the	_
12-23	2368-2373	Bronx	_
12-24	2374-2376	VA	_
12-25	2377-2384	Medical	_
12-26	2385-2391	Center	_
12-27	2392-2394	in	_
12-28	2395-2398	the	_
12-29	2399-2402	New	_
12-30	2403-2407	York	_
12-31	2408-2420	metropolitan	_
12-32	2421-2425	area	_
12-33	2426-2427	.	_

Text=They varied in illness chronicity (duration of illness = 15.77±15.64 years, ranging from 1 to 59 years) and level of social functioning (14 with Kraepelinian schizophrenia subtype, 27 with non-Kraepelinian subtype, based on criteria of).
13-1	2428-2432	They	_
13-2	2433-2439	varied	_
13-3	2440-2442	in	_
13-4	2443-2450	illness	_
13-5	2451-2461	chronicity	_
13-6	2462-2463	(	_
13-7	2464-2472	duration	_
13-8	2473-2475	of	_
13-9	2476-2483	illness	_
13-10	2484-2485	=	_
13-11	2486-2497	15.77±15.64	_
13-12	2498-2503	years	_
13-13	2504-2505	,	_
13-14	2506-2513	ranging	_
13-15	2514-2518	from	_
13-16	2519-2520	1	_
13-17	2521-2523	to	_
13-18	2524-2526	59	_
13-19	2527-2532	years	_
13-20	2533-2534	)	_
13-21	2535-2538	and	_
13-22	2539-2544	level	_
13-23	2545-2547	of	_
13-24	2548-2554	social	_
13-25	2555-2566	functioning	_
13-26	2567-2568	(	_
13-27	2569-2571	14	_
13-28	2572-2576	with	_
13-29	2577-2589	Kraepelinian	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-30	2590-2603	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-31	2604-2611	subtype	_
13-32	2612-2613	,	_
13-33	2614-2616	27	_
13-34	2617-2621	with	_
13-35	2622-2638	non-Kraepelinian	_
13-36	2639-2646	subtype	_
13-37	2647-2648	,	_
13-38	2649-2654	based	_
13-39	2655-2657	on	_
13-40	2658-2666	criteria	_
13-41	2667-2669	of	_
13-42	2670-2671	)	_
13-43	2672-2673	.	_

Text=PANSS scores were 19.14±7.0 (positive), 19.24±7.2 (negative) and 38.36±11.0 (general).
14-1	2674-2679	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
14-2	2680-2686	scores	_
14-3	2687-2691	were	_
14-4	2692-2701	19.14±7.0	_
14-5	2702-2703	(	_
14-6	2704-2712	positive	_
14-7	2713-2714	)	_
14-8	2715-2716	,	_
14-9	2717-2726	19.24±7.2	_
14-10	2727-2728	(	_
14-11	2729-2737	negative	_
14-12	2738-2739	)	_
14-13	2740-2743	and	_
14-14	2744-2754	38.36±11.0	_
14-15	2755-2756	(	_
14-16	2757-2764	general	_
14-17	2765-2766	)	_
14-18	2767-2768	.	_

Text=Subjects with ASD were recruited by advertisements at the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
15-1	2769-2777	Subjects	_
15-2	2778-2782	with	_
15-3	2783-2786	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-4	2787-2791	were	_
15-5	2792-2801	recruited	_
15-6	2802-2804	by	_
15-7	2805-2819	advertisements	_
15-8	2820-2822	at	_
15-9	2823-2826	the	_
15-10	2827-2833	Seaver	_
15-11	2834-2840	Autism	_
15-12	2841-2847	Center	_
15-13	2848-2850	at	_
15-14	2851-2854	the	_
15-15	2855-2860	Icahn	_
15-16	2861-2867	School	_
15-17	2868-2870	of	_
15-18	2871-2879	Medicine	_
15-19	2880-2882	at	_
15-20	2883-2888	Mount	_
15-21	2889-2894	Sinai	_
15-22	2895-2896	.	_

Text=Diagnosis was confirmed by both DSM-IV criteria and Autism Diagnostic Interview-Revised.
16-1	2897-2906	Diagnosis	_
16-2	2907-2910	was	_
16-3	2911-2920	confirmed	_
16-4	2921-2923	by	_
16-5	2924-2928	both	_
16-6	2929-2935	DSM-IV	_
16-7	2936-2944	criteria	_
16-8	2945-2948	and	_
16-9	2949-2955	Autism	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-10	2956-2966	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-11	2967-2984	Interview-Revised	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
16-12	2985-2986	.	_

Text=ASD subjects were verbal and were administered the WAIS and the Raven ’ s Progressive Matrices (not available for 6 participants).
17-1	2987-2990	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-2	2991-2999	subjects	_
17-3	3000-3004	were	_
17-4	3005-3011	verbal	_
17-5	3012-3015	and	_
17-6	3016-3020	were	_
17-7	3021-3033	administered	_
17-8	3034-3037	the	_
17-9	3038-3042	WAIS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-10	3043-3046	and	_
17-11	3047-3050	the	_
17-12	3051-3056	Raven	_
17-13	3057-3058	’	_
17-14	3059-3060	s	_
17-15	3061-3072	Progressive	_
17-16	3073-3081	Matrices	_
17-17	3082-3083	(	_
17-18	3084-3087	not	_
17-19	3088-3097	available	_
17-20	3098-3101	for	_
17-21	3102-3103	6	_
17-22	3104-3116	participants	_
17-23	3117-3118	)	_
17-24	3119-3120	.	_

Text=The mean full-scale IQ score for the ASD group was 108.80±20.25 (verbal IQ=110.15±20.70, performance IQ=105.70±19.93).
18-1	3121-3124	The	_
18-2	3125-3129	mean	_
18-3	3130-3140	full-scale	_
18-4	3141-3143	IQ	_
18-5	3144-3149	score	_
18-6	3150-3153	for	_
18-7	3154-3157	the	_
18-8	3158-3161	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-9	3162-3167	group	_
18-10	3168-3171	was	_
18-11	3172-3184	108.80±20.25	_
18-12	3185-3186	(	_
18-13	3187-3193	verbal	_
18-14	3194-3209	IQ=110.15±20.70	_
18-15	3210-3211	,	_
18-16	3212-3223	performance	_
18-17	3224-3239	IQ=105.70±19.93	_
18-18	3240-3241	)	_
18-19	3242-3243	.	_

Text=All ASD and schizophrenia participants were unmedicated with psychotropic substances for at least 14 days prior to scan date.
19-1	3244-3247	All	_
19-2	3248-3251	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-3	3252-3255	and	_
19-4	3256-3269	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-5	3270-3282	participants	_
19-6	3283-3287	were	_
19-7	3288-3299	unmedicated	_
19-8	3300-3304	with	_
19-9	3305-3317	psychotropic	_
19-10	3318-3328	substances	_
19-11	3329-3332	for	_
19-12	3333-3335	at	_
19-13	3336-3341	least	_
19-14	3342-3344	14	_
19-15	3345-3349	days	_
19-16	3350-3355	prior	_
19-17	3356-3358	to	_
19-18	3359-3363	scan	_
19-19	3364-3368	date	_
19-20	3369-3370	.	_

Text=Study participants in the present report were also part of our structural MRI comparison of subjects with schizophrenia and ASD and of FDG PET comparison of subjects with Kraepelinian and non-Kraepelinian schizophrenia, subsample of ASD subjects featured in and.
20-1	3371-3376	Study	_
20-2	3377-3389	participants	_
20-3	3390-3392	in	_
20-4	3393-3396	the	_
20-5	3397-3404	present	_
20-6	3405-3411	report	_
20-7	3412-3416	were	_
20-8	3417-3421	also	_
20-9	3422-3426	part	_
20-10	3427-3429	of	_
20-11	3430-3433	our	_
20-12	3434-3444	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
20-13	3445-3448	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
20-14	3449-3459	comparison	_
20-15	3460-3462	of	_
20-16	3463-3471	subjects	_
20-17	3472-3476	with	_
20-18	3477-3490	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-19	3491-3494	and	_
20-20	3495-3498	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-21	3499-3502	and	_
20-22	3503-3505	of	_
20-23	3506-3509	FDG	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
20-24	3510-3513	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
20-25	3514-3524	comparison	_
20-26	3525-3527	of	_
20-27	3528-3536	subjects	_
20-28	3537-3541	with	_
20-29	3542-3554	Kraepelinian	_
20-30	3555-3558	and	_
20-31	3559-3575	non-Kraepelinian	_
20-32	3576-3589	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-33	3590-3591	,	_
20-34	3592-3601	subsample	_
20-35	3602-3604	of	_
20-36	3605-3608	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-37	3609-3617	subjects	_
20-38	3618-3626	featured	_
20-39	3627-3629	in	_
20-40	3630-3633	and	_
20-41	3634-3635	.	_

Text=In comparison to the latter two studies, the present report employs a larger cohort of participants, analyzes different regions of interest with a newer automated region-of-interest approach.
21-1	3636-3638	In	_
21-2	3639-3649	comparison	_
21-3	3650-3652	to	_
21-4	3653-3656	the	_
21-5	3657-3663	latter	_
21-6	3664-3667	two	_
21-7	3668-3675	studies	_
21-8	3676-3677	,	_
21-9	3678-3681	the	_
21-10	3682-3689	present	_
21-11	3690-3696	report	_
21-12	3697-3704	employs	_
21-13	3705-3706	a	_
21-14	3707-3713	larger	_
21-15	3714-3720	cohort	_
21-16	3721-3723	of	_
21-17	3724-3736	participants	_
21-18	3737-3738	,	_
21-19	3739-3747	analyzes	_
21-20	3748-3757	different	_
21-21	3758-3765	regions	_
21-22	3766-3768	of	_
21-23	3769-3777	interest	_
21-24	3778-3782	with	_
21-25	3783-3784	a	_
21-26	3785-3790	newer	_
21-27	3791-3800	automated	_
21-28	3801-3819	region-of-interest	_
21-29	3820-3828	approach	_
21-30	3829-3830	.	_

Text=Data acquisition and processing All participants had a negative urine screen for drugs of abuse and all women also had a negative pregnancy test on scan day.
22-1	3831-3835	Data	_
22-2	3836-3847	acquisition	_
22-3	3848-3851	and	_
22-4	3852-3862	processing	_
22-5	3863-3866	All	_
22-6	3867-3879	participants	_
22-7	3880-3883	had	_
22-8	3884-3885	a	_
22-9	3886-3894	negative	_
22-10	3895-3900	urine	_
22-11	3901-3907	screen	_
22-12	3908-3911	for	_
22-13	3912-3917	drugs	_
22-14	3918-3920	of	_
22-15	3921-3926	abuse	_
22-16	3927-3930	and	_
22-17	3931-3934	all	_
22-18	3935-3940	women	_
22-19	3941-3945	also	_
22-20	3946-3949	had	_
22-21	3950-3951	a	_
22-22	3952-3960	negative	_
22-23	3961-3970	pregnancy	_
22-24	3971-3975	test	_
22-25	3976-3978	on	_
22-26	3979-3983	scan	_
22-27	3984-3987	day	_
22-28	3988-3989	.	_

Text=An intravenous line was inserted into a forearm vein in each arm of the subject and kept patent by normal saline, 50–75 ml/h.
23-1	3990-3992	An	_
23-2	3993-4004	intravenous	_
23-3	4005-4009	line	_
23-4	4010-4013	was	_
23-5	4014-4022	inserted	_
23-6	4023-4027	into	_
23-7	4028-4029	a	_
23-8	4030-4037	forearm	_
23-9	4038-4042	vein	_
23-10	4043-4045	in	_
23-11	4046-4050	each	_
23-12	4051-4054	arm	_
23-13	4055-4057	of	_
23-14	4058-4061	the	_
23-15	4062-4069	subject	_
23-16	4070-4073	and	_
23-17	4074-4078	kept	_
23-18	4079-4085	patent	_
23-19	4086-4088	by	_
23-20	4089-4095	normal	_
23-21	4096-4102	saline	_
23-22	4103-4104	,	_
23-23	4105-4110	50–75	_
23-24	4111-4115	ml/h	_
23-25	4116-4117	.	_

Text=The subject was instructed on the serial verbal learning task (SVLT) prior to isotope injection in the sound-attenuated uptake room in the Mount Sinai PET Center.
24-1	4118-4121	The	_
24-2	4122-4129	subject	_
24-3	4130-4133	was	_
24-4	4134-4144	instructed	_
24-5	4145-4147	on	_
24-6	4148-4151	the	_
24-7	4152-4158	serial	http://maven.renci.org/NeuroBridge/neurobridge#II
24-8	4159-4165	verbal	http://maven.renci.org/NeuroBridge/neurobridge#II
24-9	4166-4174	learning	http://maven.renci.org/NeuroBridge/neurobridge#II
24-10	4175-4179	task	http://maven.renci.org/NeuroBridge/neurobridge#II
24-11	4180-4181	(	http://maven.renci.org/NeuroBridge/neurobridge#II
24-12	4182-4186	SVLT	http://maven.renci.org/NeuroBridge/neurobridge#II
24-13	4187-4188	)	http://maven.renci.org/NeuroBridge/neurobridge#II
24-14	4189-4194	prior	_
24-15	4195-4197	to	_
24-16	4198-4205	isotope	_
24-17	4206-4215	injection	_
24-18	4216-4218	in	_
24-19	4219-4222	the	_
24-20	4223-4239	sound-attenuated	_
24-21	4240-4246	uptake	_
24-22	4247-4251	room	_
24-23	4252-4254	in	_
24-24	4255-4258	the	_
24-25	4259-4264	Mount	_
24-26	4265-4270	Sinai	_
24-27	4271-4274	PET	_
24-28	4275-4281	Center	_
24-29	4282-4283	.	_

Text=The serial verbal learning task (see for task details) was initiated on a computer screen directly in front of the subject.
25-1	4284-4287	The	_
25-2	4288-4294	serial	_
25-3	4295-4301	verbal	http://maven.renci.org/NeuroBridge/neurobridge#II
25-4	4302-4310	learning	http://maven.renci.org/NeuroBridge/neurobridge#II
25-5	4311-4315	task	http://maven.renci.org/NeuroBridge/neurobridge#II
25-6	4316-4317	(	_
25-7	4318-4321	see	_
25-8	4322-4325	for	_
25-9	4326-4330	task	_
25-10	4331-4338	details	_
25-11	4339-4340	)	_
25-12	4341-4344	was	_
25-13	4345-4354	initiated	_
25-14	4355-4357	on	_
25-15	4358-4359	a	_
25-16	4360-4368	computer	_
25-17	4369-4375	screen	_
25-18	4376-4384	directly	_
25-19	4385-4387	in	_
25-20	4388-4393	front	_
25-21	4394-4396	of	_
25-22	4397-4400	the	_
25-23	4401-4408	subject	_
25-24	4409-4410	.	_

Text=Immediately upon starting the SVLT, 5 mCi of 18FDG (185 Mbq) were administered into the venous set rubber diaphragm behind the subject ’ s back as a 45–60 seconds slow push.
26-1	4411-4422	Immediately	_
26-2	4423-4427	upon	_
26-3	4428-4436	starting	_
26-4	4437-4440	the	_
26-5	4441-4445	SVLT	_
26-6	4446-4447	,	_
26-7	4448-4449	5	_
26-8	4450-4453	mCi	_
26-9	4454-4456	of	_
26-10	4457-4462	18FDG	_
26-11	4463-4464	(	_
26-12	4465-4468	185	_
26-13	4469-4472	Mbq	_
26-14	4473-4474	)	_
26-15	4475-4479	were	_
26-16	4480-4492	administered	_
26-17	4493-4497	into	_
26-18	4498-4501	the	_
26-19	4502-4508	venous	_
26-20	4509-4512	set	_
26-21	4513-4519	rubber	_
26-22	4520-4529	diaphragm	_
26-23	4530-4536	behind	_
26-24	4537-4540	the	_
26-25	4541-4548	subject	_
26-26	4549-4550	’	_
26-27	4551-4552	s	_
26-28	4553-4557	back	_
26-29	4558-4560	as	_
26-30	4561-4562	a	_
26-31	4563-4568	45–60	_
26-32	4569-4576	seconds	_
26-33	4577-4581	slow	_
26-34	4582-4586	push	_
26-35	4587-4588	.	_

Text=The tube was clamped above the port before administration; after administration the saline was allowed to run at maximum rate for 6 minutes to flush the line, which was then closed.
27-1	4589-4592	The	_
27-2	4593-4597	tube	_
27-3	4598-4601	was	_
27-4	4602-4609	clamped	_
27-5	4610-4615	above	_
27-6	4616-4619	the	_
27-7	4620-4624	port	_
27-8	4625-4631	before	_
27-9	4632-4646	administration	_
27-10	4647-4648	;	_
27-11	4649-4654	after	_
27-12	4655-4669	administration	_
27-13	4670-4673	the	_
27-14	4674-4680	saline	_
27-15	4681-4684	was	_
27-16	4685-4692	allowed	_
27-17	4693-4695	to	_
27-18	4696-4699	run	_
27-19	4700-4702	at	_
27-20	4703-4710	maximum	_
27-21	4711-4715	rate	_
27-22	4716-4719	for	_
27-23	4720-4721	6	_
27-24	4722-4729	minutes	_
27-25	4730-4732	to	_
27-26	4733-4738	flush	_
27-27	4739-4742	the	_
27-28	4743-4747	line	_
27-29	4748-4749	,	_
27-30	4750-4755	which	_
27-31	4756-4759	was	_
27-32	4760-4764	then	_
27-33	4765-4771	closed	_
27-34	4772-4773	.	_

Text=The subject remained in the uptake room and performed the SVLT for 32 minutes before being escorted to the adjacent bathroom to void, then positioned in the scanner using their own premolded thermosetting plastic mask.
28-1	4774-4777	The	_
28-2	4778-4785	subject	_
28-3	4786-4794	remained	_
28-4	4795-4797	in	_
28-5	4798-4801	the	_
28-6	4802-4808	uptake	_
28-7	4809-4813	room	_
28-8	4814-4817	and	_
28-9	4818-4827	performed	_
28-10	4828-4831	the	_
28-11	4832-4836	SVLT	_
28-12	4837-4840	for	_
28-13	4841-4843	32	_
28-14	4844-4851	minutes	_
28-15	4852-4858	before	_
28-16	4859-4864	being	_
28-17	4865-4873	escorted	_
28-18	4874-4876	to	_
28-19	4877-4880	the	_
28-20	4881-4889	adjacent	_
28-21	4890-4898	bathroom	_
28-22	4899-4901	to	_
28-23	4902-4906	void	_
28-24	4907-4908	,	_
28-25	4909-4913	then	_
28-26	4914-4924	positioned	_
28-27	4925-4927	in	_
28-28	4928-4931	the	_
28-29	4932-4939	scanner	_
28-30	4940-4945	using	_
28-31	4946-4951	their	_
28-32	4952-4955	own	_
28-33	4956-4965	premolded	_
28-34	4966-4979	thermosetting	_
28-35	4980-4987	plastic	_
28-36	4988-4992	mask	_
28-37	4993-4994	.	_

Text=Imaging data acquisition lasted approximately 40 minutes.
29-1	4995-5002	Imaging	_
29-2	5003-5007	data	_
29-3	5008-5019	acquisition	_
29-4	5020-5026	lasted	_
29-5	5027-5040	approximately	_
29-6	5041-5043	40	_
29-7	5044-5051	minutes	_
29-8	5052-5053	.	_

Text=The PET scans were obtained with a head-dedicated scanner (GE Medical Systems model 2048) with measured resolution of 4.5 mm in plane (4.2–4.5 mm across 15 planes) and 5.0 mm axially.
30-1	5054-5057	The	_
30-2	5058-5061	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-3	5062-5067	scans	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-4	5068-5072	were	_
30-5	5073-5081	obtained	_
30-6	5082-5086	with	_
30-7	5087-5088	a	_
30-8	5089-5103	head-dedicated	_
30-9	5104-5111	scanner	_
30-10	5112-5113	(	_
30-11	5114-5116	GE	_
30-12	5117-5124	Medical	_
30-13	5125-5132	Systems	_
30-14	5133-5138	model	_
30-15	5139-5143	2048	_
30-16	5144-5145	)	_
30-17	5146-5150	with	_
30-18	5151-5159	measured	_
30-19	5160-5170	resolution	_
30-20	5171-5173	of	_
30-21	5174-5177	4.5	_
30-22	5178-5180	mm	_
30-23	5181-5183	in	_
30-24	5184-5189	plane	_
30-25	5190-5191	(	_
30-26	5192-5199	4.2–4.5	_
30-27	5200-5202	mm	_
30-28	5203-5209	across	_
30-29	5210-5212	15	_
30-30	5213-5219	planes	_
30-31	5220-5221	)	_
30-32	5222-5225	and	_
30-33	5226-5229	5.0	_
30-34	5230-5232	mm	_
30-35	5233-5240	axially	_
30-36	5241-5242	.	_

Text=15 slices at 6.5-mm intervals were obtained in two sets so as to cover the entire brain.
31-1	5243-5245	15	_
31-2	5246-5252	slices	_
31-3	5253-5255	at	_
31-4	5256-5262	6.5-mm	_
31-5	5263-5272	intervals	_
31-6	5273-5277	were	_
31-7	5278-5286	obtained	_
31-8	5287-5289	in	_
31-9	5290-5293	two	_
31-10	5294-5298	sets	_
31-11	5299-5301	so	_
31-12	5302-5304	as	_
31-13	5305-5307	to	_
31-14	5308-5313	cover	_
31-15	5314-5317	the	_
31-16	5318-5324	entire	_
31-17	5325-5330	brain	_
31-18	5331-5332	.	_

Text=Slice counts of 1.5–3 M were typical.
32-1	5333-5338	Slice	_
32-2	5339-5345	counts	_
32-3	5346-5348	of	_
32-4	5349-5354	1.5–3	_
32-5	5355-5356	M	_
32-6	5357-5361	were	_
32-7	5362-5369	typical	_
32-8	5370-5371	.	_

Text=Scans were reconstructed with a blank transmission scan and the Hann filter.
33-1	5372-5377	Scans	_
33-2	5378-5382	were	_
33-3	5383-5396	reconstructed	_
33-4	5397-5401	with	_
33-5	5402-5403	a	_
33-6	5404-5409	blank	_
33-7	5410-5422	transmission	_
33-8	5423-5427	scan	_
33-9	5428-5431	and	_
33-10	5432-5435	the	_
33-11	5436-5440	Hann	_
33-12	5441-5447	filter	_
33-13	5448-5449	.	_

Text=The SVLT, based on the principles of the California Verbal Learning Test, consists of five word lists containing 16 words each divided into 4 semantic categories (e.g., colors, animals, desserts, drinks).
34-1	5450-5453	The	_
34-2	5454-5458	SVLT	_
34-3	5459-5460	,	_
34-4	5461-5466	based	_
34-5	5467-5469	on	_
34-6	5470-5473	the	_
34-7	5474-5484	principles	_
34-8	5485-5487	of	_
34-9	5488-5491	the	_
34-10	5492-5502	California	_
34-11	5503-5509	Verbal	_
34-12	5510-5518	Learning	_
34-13	5519-5523	Test	_
34-14	5524-5525	,	_
34-15	5526-5534	consists	_
34-16	5535-5537	of	_
34-17	5538-5542	five	_
34-18	5543-5547	word	_
34-19	5548-5553	lists	_
34-20	5554-5564	containing	_
34-21	5565-5567	16	_
34-22	5568-5573	words	_
34-23	5574-5578	each	_
34-24	5579-5586	divided	_
34-25	5587-5591	into	_
34-26	5592-5593	4	_
34-27	5594-5602	semantic	_
34-28	5603-5613	categories	_
34-29	5614-5615	(	_
34-30	5616-5620	e.g.	_
34-31	5621-5622	,	_
34-32	5623-5629	colors	_
34-33	5630-5631	,	_
34-34	5632-5639	animals	_
34-35	5640-5641	,	_
34-36	5642-5650	desserts	_
34-37	5651-5652	,	_
34-38	5653-5659	drinks	_
34-39	5660-5661	)	_
34-40	5662-5663	.	_

Text=Each of the five lists is presented on a computer monitor five times at a rate of one word every 1.5 seconds, avoiding consecutive presentation of words from the same semantic category.
35-1	5664-5668	Each	_
35-2	5669-5671	of	_
35-3	5672-5675	the	_
35-4	5676-5680	five	_
35-5	5681-5686	lists	_
35-6	5687-5689	is	_
35-7	5690-5699	presented	_
35-8	5700-5702	on	_
35-9	5703-5704	a	_
35-10	5705-5713	computer	_
35-11	5714-5721	monitor	_
35-12	5722-5726	five	_
35-13	5727-5732	times	_
35-14	5733-5735	at	_
35-15	5736-5737	a	_
35-16	5738-5742	rate	_
35-17	5743-5745	of	_
35-18	5746-5749	one	_
35-19	5750-5754	word	_
35-20	5755-5760	every	_
35-21	5761-5764	1.5	_
35-22	5765-5772	seconds	_
35-23	5773-5774	,	_
35-24	5775-5783	avoiding	_
35-25	5784-5795	consecutive	_
35-26	5796-5808	presentation	_
35-27	5809-5811	of	_
35-28	5812-5817	words	_
35-29	5818-5822	from	_
35-30	5823-5826	the	_
35-31	5827-5831	same	_
35-32	5832-5840	semantic	_
35-33	5841-5849	category	_
35-34	5850-5851	.	_

Text=Ordering of the words within each list, as well as the presentation order of each list were identical for all participants.
36-1	5852-5860	Ordering	_
36-2	5861-5863	of	_
36-3	5864-5867	the	_
36-4	5868-5873	words	_
36-5	5874-5880	within	_
36-6	5881-5885	each	_
36-7	5886-5890	list	_
36-8	5891-5892	,	_
36-9	5893-5895	as	_
36-10	5896-5900	well	_
36-11	5901-5903	as	_
36-12	5904-5907	the	_
36-13	5908-5920	presentation	_
36-14	5921-5926	order	_
36-15	5927-5929	of	_
36-16	5930-5934	each	_
36-17	5935-5939	list	_
36-18	5940-5944	were	_
36-19	5945-5954	identical	_
36-20	5955-5958	for	_
36-21	5959-5962	all	_
36-22	5963-5975	participants	_
36-23	5976-5977	.	_

Text=The participants read each word aloud as it appeared on the computer monitor to maintain steady focus of attention on the task.
37-1	5978-5981	The	_
37-2	5982-5994	participants	_
37-3	5995-5999	read	_
37-4	6000-6004	each	_
37-5	6005-6009	word	_
37-6	6010-6015	aloud	_
37-7	6016-6018	as	_
37-8	6019-6021	it	_
37-9	6022-6030	appeared	_
37-10	6031-6033	on	_
37-11	6034-6037	the	_
37-12	6038-6046	computer	_
37-13	6047-6054	monitor	_
37-14	6055-6057	to	_
37-15	6058-6066	maintain	_
37-16	6067-6073	steady	_
37-17	6074-6079	focus	_
37-18	6080-6082	of	_
37-19	6083-6092	attention	_
37-20	6093-6095	on	_
37-21	6096-6099	the	_
37-22	6100-6104	task	_
37-23	6105-6106	.	_

Text=After completion of each 16-word module, participants are asked to recall as many words as they remembered.
38-1	6107-6112	After	_
38-2	6113-6123	completion	_
38-3	6124-6126	of	_
38-4	6127-6131	each	_
38-5	6132-6139	16-word	_
38-6	6140-6146	module	_
38-7	6147-6148	,	_
38-8	6149-6161	participants	_
38-9	6162-6165	are	_
38-10	6166-6171	asked	_
38-11	6172-6174	to	_
38-12	6175-6181	recall	_
38-13	6182-6184	as	_
38-14	6185-6189	many	_
38-15	6190-6195	words	_
38-16	6196-6198	as	_
38-17	6199-6203	they	_
38-18	6204-6214	remembered	_
38-19	6215-6216	.	_

Text=Each list was repeated five times before moving to the next 16-word list.
39-1	6217-6221	Each	_
39-2	6222-6226	list	_
39-3	6227-6230	was	_
39-4	6231-6239	repeated	_
39-5	6240-6244	five	_
39-6	6245-6250	times	_
39-7	6251-6257	before	_
39-8	6258-6264	moving	_
39-9	6265-6267	to	_
39-10	6268-6271	the	_
39-11	6272-6276	next	_
39-12	6277-6284	16-word	_
39-13	6285-6289	list	_
39-14	6290-6291	.	_

Text=Responses were scored for total number of correctly recalled words, recall by semantic clustering, recall by serial order, intrusions, and perseverations; each of these scores was averaged across trials.
40-1	6292-6301	Responses	_
40-2	6302-6306	were	_
40-3	6307-6313	scored	_
40-4	6314-6317	for	_
40-5	6318-6323	total	_
40-6	6324-6330	number	_
40-7	6331-6333	of	_
40-8	6334-6343	correctly	_
40-9	6344-6352	recalled	_
40-10	6353-6358	words	_
40-11	6359-6360	,	_
40-12	6361-6367	recall	_
40-13	6368-6370	by	_
40-14	6371-6379	semantic	_
40-15	6380-6390	clustering	_
40-16	6391-6392	,	_
40-17	6393-6399	recall	_
40-18	6400-6402	by	_
40-19	6403-6409	serial	_
40-20	6410-6415	order	_
40-21	6416-6417	,	_
40-22	6418-6428	intrusions	_
40-23	6429-6430	,	_
40-24	6431-6434	and	_
40-25	6435-6449	perseverations	_
40-26	6450-6451	;	_
40-27	6452-6456	each	_
40-28	6457-6459	of	_
40-29	6460-6465	these	_
40-30	6466-6472	scores	_
40-31	6473-6476	was	_
40-32	6477-6485	averaged	_
40-33	6486-6492	across	_
40-34	6493-6499	trials	_
40-35	6500-6501	.	_

Text=The semantic clustering score was defined as the number of contiguously recalled correct words from the same semantic category, yielding a maximum potential score of 12 clustered words per list.
41-1	6502-6505	The	_
41-2	6506-6514	semantic	_
41-3	6515-6525	clustering	_
41-4	6526-6531	score	_
41-5	6532-6535	was	_
41-6	6536-6543	defined	_
41-7	6544-6546	as	_
41-8	6547-6550	the	_
41-9	6551-6557	number	_
41-10	6558-6560	of	_
41-11	6561-6573	contiguously	_
41-12	6574-6582	recalled	_
41-13	6583-6590	correct	_
41-14	6591-6596	words	_
41-15	6597-6601	from	_
41-16	6602-6605	the	_
41-17	6606-6610	same	_
41-18	6611-6619	semantic	_
41-19	6620-6628	category	_
41-20	6629-6630	,	_
41-21	6631-6639	yielding	_
41-22	6640-6641	a	_
41-23	6642-6649	maximum	_
41-24	6650-6659	potential	_
41-25	6660-6665	score	_
41-26	6666-6668	of	_
41-27	6669-6671	12	_
41-28	6672-6681	clustered	_
41-29	6682-6687	words	_
41-30	6688-6691	per	_
41-31	6692-6696	list	_
41-32	6697-6698	.	_

Text=The serial-order score was defined as the number of contiguously recalled items in the same relative order as presented on the list, yielding a maximum of 15 ordered words per list.
42-1	6699-6702	The	_
42-2	6703-6715	serial-order	_
42-3	6716-6721	score	_
42-4	6722-6725	was	_
42-5	6726-6733	defined	_
42-6	6734-6736	as	_
42-7	6737-6740	the	_
42-8	6741-6747	number	_
42-9	6748-6750	of	_
42-10	6751-6763	contiguously	_
42-11	6764-6772	recalled	_
42-12	6773-6778	items	_
42-13	6779-6781	in	_
42-14	6782-6785	the	_
42-15	6786-6790	same	_
42-16	6791-6799	relative	_
42-17	6800-6805	order	_
42-18	6806-6808	as	_
42-19	6809-6818	presented	_
42-20	6819-6821	on	_
42-21	6822-6825	the	_
42-22	6826-6830	list	_
42-23	6831-6832	,	_
42-24	6833-6841	yielding	_
42-25	6842-6843	a	_
42-26	6844-6851	maximum	_
42-27	6852-6854	of	_
42-28	6855-6857	15	_
42-29	6858-6865	ordered	_
42-30	6866-6871	words	_
42-31	6872-6875	per	_
42-32	6876-6880	list	_
42-33	6881-6882	.	_

Text=Intrusions were defined as the number of words named that did not appear on the current word list, and perseverations were defined as the number of words repeated within the same trial.
43-1	6883-6893	Intrusions	_
43-2	6894-6898	were	_
43-3	6899-6906	defined	_
43-4	6907-6909	as	_
43-5	6910-6913	the	_
43-6	6914-6920	number	_
43-7	6921-6923	of	_
43-8	6924-6929	words	_
43-9	6930-6935	named	_
43-10	6936-6940	that	_
43-11	6941-6944	did	_
43-12	6945-6948	not	_
43-13	6949-6955	appear	_
43-14	6956-6958	on	_
43-15	6959-6962	the	_
43-16	6963-6970	current	_
43-17	6971-6975	word	_
43-18	6976-6980	list	_
43-19	6981-6982	,	_
43-20	6983-6986	and	_
43-21	6987-7001	perseverations	_
43-22	7002-7006	were	_
43-23	7007-7014	defined	_
43-24	7015-7017	as	_
43-25	7018-7021	the	_
43-26	7022-7028	number	_
43-27	7029-7031	of	_
43-28	7032-7037	words	_
43-29	7038-7046	repeated	_
43-30	7047-7053	within	_
43-31	7054-7057	the	_
43-32	7058-7062	same	_
43-33	7063-7068	trial	_
43-34	7069-7070	.	_

Text=T1-weighted MR images were acquired using a 1.5T Signa 5× scanner (GE Medical Systems) with a 3D-SPGR sequence (TR=24 msec, TE=5 msec, flip angle=40°, matrix size=256×256, field of view=23 cm, slice thickness=1.2 mm, total slices=128, NEX=1).
44-1	7071-7082	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-2	7083-7085	MR	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-3	7086-7092	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
44-4	7093-7097	were	_
44-5	7098-7106	acquired	_
44-6	7107-7112	using	_
44-7	7113-7114	a	_
44-8	7115-7119	1.5T	_
44-9	7120-7125	Signa	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
44-10	7126-7128	5×	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
44-11	7129-7136	scanner	_
44-12	7137-7138	(	_
44-13	7139-7141	GE	_
44-14	7142-7149	Medical	_
44-15	7150-7157	Systems	_
44-16	7158-7159	)	_
44-17	7160-7164	with	_
44-18	7165-7166	a	_
44-19	7167-7174	3D-SPGR	_
44-20	7175-7183	sequence	_
44-21	7184-7185	(	_
44-22	7186-7191	TR=24	_
44-23	7192-7196	msec	_
44-24	7197-7198	,	_
44-25	7199-7203	TE=5	_
44-26	7204-7208	msec	_
44-27	7209-7210	,	_
44-28	7211-7215	flip	_
44-29	7216-7225	angle=40°	_
44-30	7226-7227	,	_
44-31	7228-7234	matrix	_
44-32	7235-7247	size=256×256	_
44-33	7248-7249	,	_
44-34	7250-7255	field	_
44-35	7256-7258	of	_
44-36	7259-7266	view=23	_
44-37	7267-7269	cm	_
44-38	7270-7271	,	_
44-39	7272-7277	slice	_
44-40	7278-7291	thickness=1.2	_
44-41	7292-7294	mm	_
44-42	7295-7296	,	_
44-43	7297-7302	total	_
44-44	7303-7313	slices=128	_
44-45	7314-7315	,	_
44-46	7316-7321	NEX=1	_
44-47	7322-7323	)	_
44-48	7324-7325	.	_

Text=Anatomical SPGR MR images were resectioned to standard Talairach-Tournoux position using the protocol of and a 6-parameter rigid-body transformation.
45-1	7326-7336	Anatomical	_
45-2	7337-7341	SPGR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
45-3	7342-7344	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
45-4	7345-7351	images	_
45-5	7352-7356	were	_
45-6	7357-7368	resectioned	_
45-7	7369-7371	to	_
45-8	7372-7380	standard	_
45-9	7381-7399	Talairach-Tournoux	_
45-10	7400-7408	position	_
45-11	7409-7414	using	_
45-12	7415-7418	the	_
45-13	7419-7427	protocol	_
45-14	7428-7430	of	_
45-15	7431-7434	and	_
45-16	7435-7436	a	_
45-17	7437-7448	6-parameter	_
45-18	7449-7459	rigid-body	_
45-19	7460-7474	transformation	_
45-20	7475-7476	.	_

Text=For analyses of 42 cortical Brodmann areas and subcortical structures we obtained FDG uptake values using the AFNI regions of interest.
46-1	7477-7480	For	_
46-2	7481-7489	analyses	_
46-3	7490-7492	of	_
46-4	7493-7495	42	_
46-5	7496-7504	cortical	_
46-6	7505-7513	Brodmann	_
46-7	7514-7519	areas	_
46-8	7520-7523	and	_
46-9	7524-7535	subcortical	_
46-10	7536-7546	structures	_
46-11	7547-7549	we	_
46-12	7550-7558	obtained	_
46-13	7559-7562	FDG	_
46-14	7563-7569	uptake	_
46-15	7570-7576	values	_
46-16	7577-7582	using	_
46-17	7583-7586	the	_
46-18	7587-7591	AFNI	_
46-19	7592-7599	regions	_
46-20	7600-7602	of	_
46-21	7603-7611	interest	_
46-22	7612-7613	.	_

Text=Only the structures featured in published literature on ASD and schizophrenia were chosen for analyses.
47-1	7614-7618	Only	_
47-2	7619-7622	the	_
47-3	7623-7633	structures	_
47-4	7634-7642	featured	_
47-5	7643-7645	in	_
47-6	7646-7655	published	_
47-7	7656-7666	literature	_
47-8	7667-7669	on	_
47-9	7670-7673	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
47-10	7674-7677	and	_
47-11	7678-7691	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
47-12	7692-7696	were	_
47-13	7697-7703	chosen	_
47-14	7704-7707	for	_
47-15	7708-7716	analyses	_
47-16	7717-7718	.	_

Text=These included the amygdala, hippocampus, cerebellar subregions (tonsil, culmen, declive, tuber, and pyramis of the vermis), basal ganglia associates structures (head, body and tail of the caudate, putamen, lateral globus pallidus, medial globus pallidus, red nucleus, substantia nigra, claustrum), mammillary body, hypothalamus, whole thalamus and thalamic nuclei (pulvinar, anteroventral, lateral dorsal, ventral lateral, ventral posteromedial, lateral posterior, ventroposterior lateral, mediodorsal, as well as the anterior and midline nuclear groups).
48-1	7719-7724	These	_
48-2	7725-7733	included	_
48-3	7734-7737	the	_
48-4	7738-7746	amygdala	_
48-5	7747-7748	,	_
48-6	7749-7760	hippocampus	_
48-7	7761-7762	,	_
48-8	7763-7773	cerebellar	_
48-9	7774-7784	subregions	_
48-10	7785-7786	(	_
48-11	7787-7793	tonsil	_
48-12	7794-7795	,	_
48-13	7796-7802	culmen	_
48-14	7803-7804	,	_
48-15	7805-7812	declive	_
48-16	7813-7814	,	_
48-17	7815-7820	tuber	_
48-18	7821-7822	,	_
48-19	7823-7826	and	_
48-20	7827-7834	pyramis	_
48-21	7835-7837	of	_
48-22	7838-7841	the	_
48-23	7842-7848	vermis	_
48-24	7849-7850	)	_
48-25	7851-7852	,	_
48-26	7853-7858	basal	_
48-27	7859-7866	ganglia	_
48-28	7867-7877	associates	_
48-29	7878-7888	structures	_
48-30	7889-7890	(	_
48-31	7891-7895	head	_
48-32	7896-7897	,	_
48-33	7898-7902	body	_
48-34	7903-7906	and	_
48-35	7907-7911	tail	_
48-36	7912-7914	of	_
48-37	7915-7918	the	_
48-38	7919-7926	caudate	_
48-39	7927-7928	,	_
48-40	7929-7936	putamen	_
48-41	7937-7938	,	_
48-42	7939-7946	lateral	_
48-43	7947-7953	globus	_
48-44	7954-7962	pallidus	_
48-45	7963-7964	,	_
48-46	7965-7971	medial	_
48-47	7972-7978	globus	_
48-48	7979-7987	pallidus	_
48-49	7988-7989	,	_
48-50	7990-7993	red	_
48-51	7994-8001	nucleus	_
48-52	8002-8003	,	_
48-53	8004-8014	substantia	_
48-54	8015-8020	nigra	_
48-55	8021-8022	,	_
48-56	8023-8032	claustrum	_
48-57	8033-8034	)	_
48-58	8035-8036	,	_
48-59	8037-8047	mammillary	_
48-60	8048-8052	body	_
48-61	8053-8054	,	_
48-62	8055-8067	hypothalamus	_
48-63	8068-8069	,	_
48-64	8070-8075	whole	_
48-65	8076-8084	thalamus	_
48-66	8085-8088	and	_
48-67	8089-8097	thalamic	_
48-68	8098-8104	nuclei	_
48-69	8105-8106	(	_
48-70	8107-8115	pulvinar	_
48-71	8116-8117	,	_
48-72	8118-8131	anteroventral	_
48-73	8132-8133	,	_
48-74	8134-8141	lateral	_
48-75	8142-8148	dorsal	_
48-76	8149-8150	,	_
48-77	8151-8158	ventral	_
48-78	8159-8166	lateral	_
48-79	8167-8168	,	_
48-80	8169-8176	ventral	_
48-81	8177-8190	posteromedial	_
48-82	8191-8192	,	_
48-83	8193-8200	lateral	_
48-84	8201-8210	posterior	_
48-85	8211-8212	,	_
48-86	8213-8228	ventroposterior	_
48-87	8229-8236	lateral	_
48-88	8237-8238	,	_
48-89	8239-8250	mediodorsal	_
48-90	8251-8252	,	_
48-91	8253-8255	as	_
48-92	8256-8260	well	_
48-93	8261-8263	as	_
48-94	8264-8267	the	_
48-95	8268-8276	anterior	_
48-96	8277-8280	and	_
48-97	8281-8288	midline	_
48-98	8289-8296	nuclear	_
48-99	8297-8303	groups	_
48-100	8304-8305	)	_
48-101	8306-8307	.	_

Text=We normalized the images by dividing each voxel value by the mean value of the whole brain, masked with the MNI brain and using slices above MNI z=-53.
49-1	8308-8310	We	_
49-2	8311-8321	normalized	_
49-3	8322-8325	the	_
49-4	8326-8332	images	_
49-5	8333-8335	by	_
49-6	8336-8344	dividing	_
49-7	8345-8349	each	_
49-8	8350-8355	voxel	_
49-9	8356-8361	value	_
49-10	8362-8364	by	_
49-11	8365-8368	the	_
49-12	8369-8373	mean	_
49-13	8374-8379	value	_
49-14	8380-8382	of	_
49-15	8383-8386	the	_
49-16	8387-8392	whole	_
49-17	8393-8398	brain	_
49-18	8399-8400	,	_
49-19	8401-8407	masked	_
49-20	8408-8412	with	_
49-21	8413-8416	the	_
49-22	8417-8420	MNI	_
49-23	8421-8426	brain	_
49-24	8427-8430	and	_
49-25	8431-8436	using	_
49-26	8437-8443	slices	_
49-27	8444-8449	above	_
49-28	8450-8453	MNI	_
49-29	8454-8459	z=-53	_
49-30	8460-8461	.	_

Text=A restricted vertical range was chosen to minimize errors in the brain extraction routine at low slice levels.
50-1	8462-8463	A	_
50-2	8464-8474	restricted	_
50-3	8475-8483	vertical	_
50-4	8484-8489	range	_
50-5	8490-8493	was	_
50-6	8494-8500	chosen	_
50-7	8501-8503	to	_
50-8	8504-8512	minimize	_
50-9	8513-8519	errors	_
50-10	8520-8522	in	_
50-11	8523-8526	the	_
50-12	8527-8532	brain	_
50-13	8533-8543	extraction	_
50-14	8544-8551	routine	_
50-15	8552-8554	at	_
50-16	8555-8558	low	_
50-17	8559-8564	slice	_
50-18	8565-8571	levels	_
50-19	8572-8573	.	_

Text=These relative metabolic rates were used in all analyses.
51-1	8574-8579	These	_
51-2	8580-8588	relative	_
51-3	8589-8598	metabolic	_
51-4	8599-8604	rates	_
51-5	8605-8609	were	_
51-6	8610-8614	used	_
51-7	8615-8617	in	_
51-8	8618-8621	all	_
51-9	8622-8630	analyses	_
51-10	8631-8632	.	_

Text=Statistical analyses Repeated-measures ANCOVA (with subjects ’ age as a covariate) was used to ascertain significant patterns of differences in glucose metabolic rates among the three diagnostic groups and then for two-group comparisons (subjects with schizophrenia vs. subjects with ASD, subjects with schizophrenia vs. healthy controls, subjects with ASD vs. healthy controls).
52-1	8633-8644	Statistical	_
52-2	8645-8653	analyses	_
52-3	8654-8671	Repeated-measures	_
52-4	8672-8678	ANCOVA	_
52-5	8679-8680	(	_
52-6	8681-8685	with	_
52-7	8686-8694	subjects	_
52-8	8695-8696	’	_
52-9	8697-8700	age	_
52-10	8701-8703	as	_
52-11	8704-8705	a	_
52-12	8706-8715	covariate	_
52-13	8716-8717	)	_
52-14	8718-8721	was	_
52-15	8722-8726	used	_
52-16	8727-8729	to	_
52-17	8730-8739	ascertain	_
52-18	8740-8751	significant	_
52-19	8752-8760	patterns	_
52-20	8761-8763	of	_
52-21	8764-8775	differences	_
52-22	8776-8778	in	_
52-23	8779-8786	glucose	_
52-24	8787-8796	metabolic	_
52-25	8797-8802	rates	_
52-26	8803-8808	among	_
52-27	8809-8812	the	_
52-28	8813-8818	three	_
52-29	8819-8829	diagnostic	_
52-30	8830-8836	groups	_
52-31	8837-8840	and	_
52-32	8841-8845	then	_
52-33	8846-8849	for	_
52-34	8850-8859	two-group	_
52-35	8860-8871	comparisons	_
52-36	8872-8873	(	_
52-37	8874-8882	subjects	_
52-38	8883-8887	with	_
52-39	8888-8901	schizophrenia	_
52-40	8902-8905	vs.	_
52-41	8906-8914	subjects	_
52-42	8915-8919	with	_
52-43	8920-8923	ASD	_
52-44	8924-8925	,	_
52-45	8926-8934	subjects	_
52-46	8935-8939	with	_
52-47	8940-8953	schizophrenia	_
52-48	8954-8957	vs.	_
52-49	8958-8965	healthy	_
52-50	8966-8974	controls	_
52-51	8975-8976	,	_
52-52	8977-8985	subjects	_
52-53	8986-8990	with	_
52-54	8991-8994	ASD	_
52-55	8995-8998	vs.	_
52-56	8999-9006	healthy	_
52-57	9007-9015	controls	_
52-58	9016-9017	)	_
52-59	9018-9019	.	_

Text=For cortical analyses, metabolic rates for each of the 42 Brodmann areas were entered into an ANCOVA with repeated measures of hemisphere and Brodmann areas.
53-1	9020-9023	For	_
53-2	9024-9032	cortical	_
53-3	9033-9041	analyses	_
53-4	9042-9043	,	_
53-5	9044-9053	metabolic	_
53-6	9054-9059	rates	_
53-7	9060-9063	for	_
53-8	9064-9068	each	_
53-9	9069-9071	of	_
53-10	9072-9075	the	_
53-11	9076-9078	42	_
53-12	9079-9087	Brodmann	_
53-13	9088-9093	areas	_
53-14	9094-9098	were	_
53-15	9099-9106	entered	_
53-16	9107-9111	into	_
53-17	9112-9114	an	_
53-18	9115-9121	ANCOVA	_
53-19	9122-9126	with	_
53-20	9127-9135	repeated	_
53-21	9136-9144	measures	_
53-22	9145-9147	of	_
53-23	9148-9158	hemisphere	_
53-24	9159-9162	and	_
53-25	9163-9171	Brodmann	_
53-26	9172-9177	areas	_
53-27	9178-9179	.	_

Text=Main effects of diagnosis, as well as higher-order group-by-hemisphere and group-by-Brodmann area interactions were assessed for hemispheric and localized intergroup differences in metabolic rates.
54-1	9180-9184	Main	_
54-2	9185-9192	effects	_
54-3	9193-9195	of	_
54-4	9196-9205	diagnosis	_
54-5	9206-9207	,	_
54-6	9208-9210	as	_
54-7	9211-9215	well	_
54-8	9216-9218	as	_
54-9	9219-9231	higher-order	_
54-10	9232-9251	group-by-hemisphere	_
54-11	9252-9255	and	_
54-12	9256-9273	group-by-Brodmann	_
54-13	9274-9278	area	_
54-14	9279-9291	interactions	_
54-15	9292-9296	were	_
54-16	9297-9305	assessed	_
54-17	9306-9309	for	_
54-18	9310-9321	hemispheric	_
54-19	9322-9325	and	_
54-20	9326-9335	localized	_
54-21	9336-9346	intergroup	_
54-22	9347-9358	differences	_
54-23	9359-9361	in	_
54-24	9362-9371	metabolic	_
54-25	9372-9377	rates	_
54-26	9378-9379	.	_

Text=These analyses of the whole cortex were followed by separate lobar analyses for constellations of Brodmann areas in each of the lobes, as well as the cingulate arch: 11 areas in the frontal lobe (4, 6, 8, 9, 10, 11, 12, 44, 45, 46, 47), 12 areas in the temporal lobe (20, 21, 22, 27, 28, 34, 35, 36, 37, 38, 41, 42), 8 areas in the parietal lobe (1, 2, 3, 5, 7, 39, 40, 43), 3 areas in the occipital lobe (17, 18, 19), and 8 areas in the cingulate (23, 24, 25, 29, 30, 31, 32, 33).
55-1	9380-9385	These	_
55-2	9386-9394	analyses	_
55-3	9395-9397	of	_
55-4	9398-9401	the	_
55-5	9402-9407	whole	_
55-6	9408-9414	cortex	_
55-7	9415-9419	were	_
55-8	9420-9428	followed	_
55-9	9429-9431	by	_
55-10	9432-9440	separate	_
55-11	9441-9446	lobar	_
55-12	9447-9455	analyses	_
55-13	9456-9459	for	_
55-14	9460-9474	constellations	_
55-15	9475-9477	of	_
55-16	9478-9486	Brodmann	_
55-17	9487-9492	areas	_
55-18	9493-9495	in	_
55-19	9496-9500	each	_
55-20	9501-9503	of	_
55-21	9504-9507	the	_
55-22	9508-9513	lobes	_
55-23	9514-9515	,	_
55-24	9516-9518	as	_
55-25	9519-9523	well	_
55-26	9524-9526	as	_
55-27	9527-9530	the	_
55-28	9531-9540	cingulate	_
55-29	9541-9545	arch	_
55-30	9546-9547	:	_
55-31	9548-9550	11	_
55-32	9551-9556	areas	_
55-33	9557-9559	in	_
55-34	9560-9563	the	_
55-35	9564-9571	frontal	_
55-36	9572-9576	lobe	_
55-37	9577-9578	(	_
55-38	9579-9580	4	_
55-39	9581-9582	,	_
55-40	9583-9584	6	_
55-41	9585-9586	,	_
55-42	9587-9588	8	_
55-43	9589-9590	,	_
55-44	9591-9592	9	_
55-45	9593-9594	,	_
55-46	9595-9597	10	_
55-47	9598-9599	,	_
55-48	9600-9602	11	_
55-49	9603-9604	,	_
55-50	9605-9607	12	_
55-51	9608-9609	,	_
55-52	9610-9612	44	_
55-53	9613-9614	,	_
55-54	9615-9617	45	_
55-55	9618-9619	,	_
55-56	9620-9622	46	_
55-57	9623-9624	,	_
55-58	9625-9627	47	_
55-59	9628-9629	)	_
55-60	9630-9631	,	_
55-61	9632-9634	12	_
55-62	9635-9640	areas	_
55-63	9641-9643	in	_
55-64	9644-9647	the	_
55-65	9648-9656	temporal	_
55-66	9657-9661	lobe	_
55-67	9662-9663	(	_
55-68	9664-9666	20	_
55-69	9667-9668	,	_
55-70	9669-9671	21	_
55-71	9672-9673	,	_
55-72	9674-9676	22	_
55-73	9677-9678	,	_
55-74	9679-9681	27	_
55-75	9682-9683	,	_
55-76	9684-9686	28	_
55-77	9687-9688	,	_
55-78	9689-9691	34	_
55-79	9692-9693	,	_
55-80	9694-9696	35	_
55-81	9697-9698	,	_
55-82	9699-9701	36	_
55-83	9702-9703	,	_
55-84	9704-9706	37	_
55-85	9707-9708	,	_
55-86	9709-9711	38	_
55-87	9712-9713	,	_
55-88	9714-9716	41	_
55-89	9717-9718	,	_
55-90	9719-9721	42	_
55-91	9722-9723	)	_
55-92	9724-9725	,	_
55-93	9726-9727	8	_
55-94	9728-9733	areas	_
55-95	9734-9736	in	_
55-96	9737-9740	the	_
55-97	9741-9749	parietal	_
55-98	9750-9754	lobe	_
55-99	9755-9756	(	_
55-100	9757-9758	1	_
55-101	9759-9760	,	_
55-102	9761-9762	2	_
55-103	9763-9764	,	_
55-104	9765-9766	3	_
55-105	9767-9768	,	_
55-106	9769-9770	5	_
55-107	9771-9772	,	_
55-108	9773-9774	7	_
55-109	9775-9776	,	_
55-110	9777-9779	39	_
55-111	9780-9781	,	_
55-112	9782-9784	40	_
55-113	9785-9786	,	_
55-114	9787-9789	43	_
55-115	9790-9791	)	_
55-116	9792-9793	,	_
55-117	9794-9795	3	_
55-118	9796-9801	areas	_
55-119	9802-9804	in	_
55-120	9805-9808	the	_
55-121	9809-9818	occipital	_
55-122	9819-9823	lobe	_
55-123	9824-9825	(	_
55-124	9826-9828	17	_
55-125	9829-9830	,	_
55-126	9831-9833	18	_
55-127	9834-9835	,	_
55-128	9836-9838	19	_
55-129	9839-9840	)	_
55-130	9841-9842	,	_
55-131	9843-9846	and	_
55-132	9847-9848	8	_
55-133	9849-9854	areas	_
55-134	9855-9857	in	_
55-135	9858-9861	the	_
55-136	9862-9871	cingulate	_
55-137	9872-9873	(	_
55-138	9874-9876	23	_
55-139	9877-9878	,	_
55-140	9879-9881	24	_
55-141	9882-9883	,	_
55-142	9884-9886	25	_
55-143	9887-9888	,	_
55-144	9889-9891	29	_
55-145	9892-9893	,	_
55-146	9894-9896	30	_
55-147	9897-9898	,	_
55-148	9899-9901	31	_
55-149	9902-9903	,	_
55-150	9904-9906	32	_
55-151	9907-9908	,	_
55-152	9909-9911	33	_
55-153	9912-9913	)	_
55-154	9914-9915	.	_

Text=In addition to univariate F, multivariate Wilks ’ λ statistics were documented for all higher-order (i.e.
56-1	9916-9918	In	_
56-2	9919-9927	addition	_
56-3	9928-9930	to	_
56-4	9931-9941	univariate	_
56-5	9942-9943	F	_
56-6	9944-9945	,	_
56-7	9946-9958	multivariate	_
56-8	9959-9964	Wilks	_
56-9	9965-9966	’	_
56-10	9967-9968	λ	_
56-11	9969-9979	statistics	_
56-12	9980-9984	were	_
56-13	9985-9995	documented	_
56-14	9996-9999	for	_
56-15	10000-10003	all	_
56-16	10004-10016	higher-order	_
56-17	10017-10018	(	_
56-18	10019-10022	i.e	_
56-19	10023-10024	.	_

Text=other than main effects) interactions.
57-1	10025-10030	other	_
57-2	10031-10035	than	_
57-3	10036-10040	main	_
57-4	10041-10048	effects	_
57-5	10049-10050	)	_
57-6	10051-10063	interactions	_
57-7	10064-10065	.	_

Text=We selected the use of repeated measures MANOVA as our strategy to counteract the problem of multiple comparisons since it reduced their number to a single group-by-Brodmann area interaction, with visual assessment of the graphed patterns.
58-1	10066-10068	We	_
58-2	10069-10077	selected	_
58-3	10078-10081	the	_
58-4	10082-10085	use	_
58-5	10086-10088	of	_
58-6	10089-10097	repeated	_
58-7	10098-10106	measures	_
58-8	10107-10113	MANOVA	_
58-9	10114-10116	as	_
58-10	10117-10120	our	_
58-11	10121-10129	strategy	_
58-12	10130-10132	to	_
58-13	10133-10143	counteract	_
58-14	10144-10147	the	_
58-15	10148-10155	problem	_
58-16	10156-10158	of	_
58-17	10159-10167	multiple	_
58-18	10168-10179	comparisons	_
58-19	10180-10185	since	_
58-20	10186-10188	it	_
58-21	10189-10196	reduced	_
58-22	10197-10202	their	_
58-23	10203-10209	number	_
58-24	10210-10212	to	_
58-25	10213-10214	a	_
58-26	10215-10221	single	_
58-27	10222-10239	group-by-Brodmann	_
58-28	10240-10244	area	_
58-29	10245-10256	interaction	_
58-30	10257-10258	,	_
58-31	10259-10263	with	_
58-32	10264-10270	visual	_
58-33	10271-10281	assessment	_
58-34	10282-10284	of	_
58-35	10285-10288	the	_
58-36	10289-10296	graphed	_
58-37	10297-10305	patterns	_
58-38	10306-10307	.	_

Text=For reference in the future replication studies, we do, however, report significant F statistics for follow-up three-group ANCOVAs on each of the individual Brodmann areas that emerge as differential in the inspection of the graphed patterns.
59-1	10308-10311	For	_
59-2	10312-10321	reference	_
59-3	10322-10324	in	_
59-4	10325-10328	the	_
59-5	10329-10335	future	_
59-6	10336-10347	replication	_
59-7	10348-10355	studies	_
59-8	10356-10357	,	_
59-9	10358-10360	we	_
59-10	10361-10363	do	_
59-11	10364-10365	,	_
59-12	10366-10373	however	_
59-13	10374-10375	,	_
59-14	10376-10382	report	_
59-15	10383-10394	significant	_
59-16	10395-10396	F	_
59-17	10397-10407	statistics	_
59-18	10408-10411	for	_
59-19	10412-10421	follow-up	_
59-20	10422-10433	three-group	_
59-21	10434-10441	ANCOVAs	_
59-22	10442-10444	on	_
59-23	10445-10449	each	_
59-24	10450-10452	of	_
59-25	10453-10456	the	_
59-26	10457-10467	individual	_
59-27	10468-10476	Brodmann	_
59-28	10477-10482	areas	_
59-29	10483-10487	that	_
59-30	10488-10494	emerge	_
59-31	10495-10497	as	_
59-32	10498-10510	differential	_
59-33	10511-10513	in	_
59-34	10514-10517	the	_
59-35	10518-10528	inspection	_
59-36	10529-10531	of	_
59-37	10532-10535	the	_
59-38	10536-10543	graphed	_
59-39	10544-10552	patterns	_
59-40	10553-10554	.	_

Text=Similar analyses were used for comparisons of relevant subcortical structures, with evaluation of main effects of diagnosis for all of them and also diagnostic group-by-region interaction for subregions of the caudate.
60-1	10555-10562	Similar	_
60-2	10563-10571	analyses	_
60-3	10572-10576	were	_
60-4	10577-10581	used	_
60-5	10582-10585	for	_
60-6	10586-10597	comparisons	_
60-7	10598-10600	of	_
60-8	10601-10609	relevant	_
60-9	10610-10621	subcortical	_
60-10	10622-10632	structures	_
60-11	10633-10634	,	_
60-12	10635-10639	with	_
60-13	10640-10650	evaluation	_
60-14	10651-10653	of	_
60-15	10654-10658	main	_
60-16	10659-10666	effects	_
60-17	10667-10669	of	_
60-18	10670-10679	diagnosis	_
60-19	10680-10683	for	_
60-20	10684-10687	all	_
60-21	10688-10690	of	_
60-22	10691-10695	them	_
60-23	10696-10699	and	_
60-24	10700-10704	also	_
60-25	10705-10715	diagnostic	_
60-26	10716-10731	group-by-region	_
60-27	10732-10743	interaction	_
60-28	10744-10747	for	_
60-29	10748-10758	subregions	_
60-30	10759-10761	of	_
60-31	10762-10765	the	_
60-32	10766-10773	caudate	_
60-33	10774-10775	.	_

Text=Age was used as a covariate due to significant age differences among three groups of participants (ANOVA F2, 118=3.47, p=0.034).
61-1	10776-10779	Age	_
61-2	10780-10783	was	_
61-3	10784-10788	used	_
61-4	10789-10791	as	_
61-5	10792-10793	a	_
61-6	10794-10803	covariate	_
61-7	10804-10807	due	_
61-8	10808-10810	to	_
61-9	10811-10822	significant	_
61-10	10823-10826	age	_
61-11	10827-10838	differences	_
61-12	10839-10844	among	_
61-13	10845-10850	three	_
61-14	10851-10857	groups	_
61-15	10858-10860	of	_
61-16	10861-10873	participants	_
61-17	10874-10875	(	_
61-18	10876-10881	ANOVA	_
61-19	10882-10884	F2	_
61-20	10885-10886	,	_
61-21	10887-10895	118=3.47	_
61-22	10896-10897	,	_
61-23	10898-10905	p=0.034	_
61-24	10906-10907	)	_
61-25	10908-10909	.	_

Text=We supplement these results (Tables 1 and 2) with ANOVAs without controlling for age as illustrated in Figures 1–4, because different age trajectories of ASD and schizophrenia may potentially render ANCOVA correction confounded.
62-1	10910-10912	We	_
62-2	10913-10923	supplement	_
62-3	10924-10929	these	_
62-4	10930-10937	results	_
62-5	10938-10939	(	_
62-6	10940-10946	Tables	_
62-7	10947-10948	1	_
62-8	10949-10952	and	_
62-9	10953-10954	2	_
62-10	10955-10956	)	_
62-11	10957-10961	with	_
62-12	10962-10968	ANOVAs	_
62-13	10969-10976	without	_
62-14	10977-10988	controlling	_
62-15	10989-10992	for	_
62-16	10993-10996	age	_
62-17	10997-10999	as	_
62-18	11000-11011	illustrated	_
62-19	11012-11014	in	_
62-20	11015-11022	Figures	_
62-21	11023-11026	1–4	_
62-22	11027-11028	,	_
62-23	11029-11036	because	_
62-24	11037-11046	different	_
62-25	11047-11050	age	_
62-26	11051-11063	trajectories	_
62-27	11064-11066	of	_
62-28	11067-11070	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
62-29	11071-11074	and	_
62-30	11075-11088	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
62-31	11089-11092	may	_
62-32	11093-11104	potentially	_
62-33	11105-11111	render	_
62-34	11112-11118	ANCOVA	_
62-35	11119-11129	correction	_
62-36	11130-11140	confounded	_
62-37	11141-11142	.	_

Text=We report all 42 Brodmann areas and 16 subcortical structures to provide a systematic database (Table 1).
63-1	11143-11145	We	_
63-2	11146-11152	report	_
63-3	11153-11156	all	_
63-4	11157-11159	42	_
63-5	11160-11168	Brodmann	_
63-6	11169-11174	areas	_
63-7	11175-11178	and	_
63-8	11179-11181	16	_
63-9	11182-11193	subcortical	_
63-10	11194-11204	structures	_
63-11	11205-11207	to	_
63-12	11208-11215	provide	_
63-13	11216-11217	a	_
63-14	11218-11228	systematic	_
63-15	11229-11237	database	_
63-16	11238-11239	(	_
63-17	11240-11245	Table	_
63-18	11246-11247	1	_
63-19	11248-11249	)	_
63-20	11250-11251	.	_

Text=Since earlier studies have tended to emphasize frontal, thalamic and striatal differences in subjects with schizophrenia and cingulate, parietal and cerebellar differences in ASD, a wide region of interest selection was important for the three-group analyses.
64-1	11252-11257	Since	_
64-2	11258-11265	earlier	_
64-3	11266-11273	studies	_
64-4	11274-11278	have	_
64-5	11279-11285	tended	_
64-6	11286-11288	to	_
64-7	11289-11298	emphasize	_
64-8	11299-11306	frontal	_
64-9	11307-11308	,	_
64-10	11309-11317	thalamic	_
64-11	11318-11321	and	_
64-12	11322-11330	striatal	_
64-13	11331-11342	differences	_
64-14	11343-11345	in	_
64-15	11346-11354	subjects	_
64-16	11355-11359	with	_
64-17	11360-11373	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
64-18	11374-11377	and	_
64-19	11378-11387	cingulate	_
64-20	11388-11389	,	_
64-21	11390-11398	parietal	_
64-22	11399-11402	and	_
64-23	11403-11413	cerebellar	_
64-24	11414-11425	differences	_
64-25	11426-11428	in	_
64-26	11429-11432	ASD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
64-27	11433-11434	,	_
64-28	11435-11436	a	_
64-29	11437-11441	wide	_
64-30	11442-11448	region	_
64-31	11449-11451	of	_
64-32	11452-11460	interest	_
64-33	11461-11470	selection	_
64-34	11471-11474	was	_
64-35	11475-11484	important	_
64-36	11485-11488	for	_
64-37	11489-11492	the	_
64-38	11493-11504	three-group	_
64-39	11505-11513	analyses	_
64-40	11514-11515	.	_

Text=Since a number of studies have reported multiple regions of significant differences in two-group analyses, we have reported uncorrected, Bonferroni corrected, and MANOVA repeated measures interactions to provide control of Type I and II error.
65-1	11516-11521	Since	_
65-2	11522-11523	a	_
65-3	11524-11530	number	_
65-4	11531-11533	of	_
65-5	11534-11541	studies	_
65-6	11542-11546	have	_
65-7	11547-11555	reported	_
65-8	11556-11564	multiple	_
65-9	11565-11572	regions	_
65-10	11573-11575	of	_
65-11	11576-11587	significant	_
65-12	11588-11599	differences	_
65-13	11600-11602	in	_
65-14	11603-11612	two-group	_
65-15	11613-11621	analyses	_
65-16	11622-11623	,	_
65-17	11624-11626	we	_
65-18	11627-11631	have	_
65-19	11632-11640	reported	_
65-20	11641-11652	uncorrected	_
65-21	11653-11654	,	_
65-22	11655-11665	Bonferroni	_
65-23	11666-11675	corrected	_
65-24	11676-11677	,	_
65-25	11678-11681	and	_
65-26	11682-11688	MANOVA	_
65-27	11689-11697	repeated	_
65-28	11698-11706	measures	_
65-29	11707-11719	interactions	_
65-30	11720-11722	to	_
65-31	11723-11730	provide	_
65-32	11731-11738	control	_
65-33	11739-11741	of	_
65-34	11742-11746	Type	_
65-35	11747-11748	I	_
65-36	11749-11752	and	_
65-37	11753-11755	II	_
65-38	11756-11761	error	_
65-39	11762-11763	.	_

Text=We applied two strategies in correcting for multiple region testing and the problem of type I error.
66-1	11764-11766	We	_
66-2	11767-11774	applied	_
66-3	11775-11778	two	_
66-4	11779-11789	strategies	_
66-5	11790-11792	in	_
66-6	11793-11803	correcting	_
66-7	11804-11807	for	_
66-8	11808-11816	multiple	_
66-9	11817-11823	region	_
66-10	11824-11831	testing	_
66-11	11832-11835	and	_
66-12	11836-11839	the	_
66-13	11840-11847	problem	_
66-14	11848-11850	of	_
66-15	11851-11855	type	_
66-16	11856-11857	I	_
66-17	11858-11863	error	_
66-18	11864-11865	.	_

Text=First, we entered the entire cortical dataset into an all-data ANOVA (42 Brodmann areas × three diagnostic groups × two hemispheres).
67-1	11866-11871	First	_
67-2	11872-11873	,	_
67-3	11874-11876	we	_
67-4	11877-11884	entered	_
67-5	11885-11888	the	_
67-6	11889-11895	entire	_
67-7	11896-11904	cortical	_
67-8	11905-11912	dataset	_
67-9	11913-11917	into	_
67-10	11918-11920	an	_
67-11	11921-11929	all-data	_
67-12	11930-11935	ANOVA	_
67-13	11936-11937	(	_
67-14	11938-11940	42	_
67-15	11941-11949	Brodmann	_
67-16	11950-11955	areas	_
67-17	11956-11957	×	_
67-18	11958-11963	three	_
67-19	11964-11974	diagnostic	_
67-20	11975-11981	groups	_
67-21	11982-11983	×	_
67-22	11984-11987	two	_
67-23	11988-11999	hemispheres	_
67-24	12000-12001	)	_
67-25	12002-12003	.	_

Text=If this was significant at the p <0.05 level, we then examined follow-up ANOVA for specific brain lobes considering main effect of group and group×Brodmann area interaction (two tests).
68-1	12004-12006	If	_
68-2	12007-12011	this	_
68-3	12012-12015	was	_
68-4	12016-12027	significant	_
68-5	12028-12030	at	_
68-6	12031-12034	the	_
68-7	12035-12036	p	_
68-8	12037-12038	<	_
68-9	12039-12043	0.05	_
68-10	12044-12049	level	_
68-11	12050-12051	,	_
68-12	12052-12054	we	_
68-13	12055-12059	then	_
68-14	12060-12068	examined	_
68-15	12069-12078	follow-up	_
68-16	12079-12084	ANOVA	_
68-17	12085-12088	for	_
68-18	12089-12097	specific	_
68-19	12098-12103	brain	_
68-20	12104-12109	lobes	_
68-21	12110-12121	considering	_
68-22	12122-12126	main	_
68-23	12127-12133	effect	_
68-24	12134-12136	of	_
68-25	12137-12142	group	_
68-26	12143-12146	and	_
68-27	12147-12161	group×Brodmann	_
68-28	12162-12166	area	_
68-29	12167-12178	interaction	_
68-30	12179-12180	(	_
68-31	12181-12184	two	_
68-32	12185-12190	tests	_
68-33	12191-12192	)	_
68-34	12193-12194	.	_

Text=However, since individual t-tests are most commonly reported in the literature we also examined follow-up group–pair ANOVA and t-tests.
69-1	12195-12202	However	_
69-2	12203-12204	,	_
69-3	12205-12210	since	_
69-4	12211-12221	individual	_
69-5	12222-12229	t-tests	_
69-6	12230-12233	are	_
69-7	12234-12238	most	_
69-8	12239-12247	commonly	_
69-9	12248-12256	reported	_
69-10	12257-12259	in	_
69-11	12260-12263	the	_
69-12	12264-12274	literature	_
69-13	12275-12277	we	_
69-14	12278-12282	also	_
69-15	12283-12291	examined	_
69-16	12292-12301	follow-up	_
69-17	12302-12312	group–pair	_
69-18	12313-12318	ANOVA	_
69-19	12319-12322	and	_
69-20	12323-12330	t-tests	_
69-21	12331-12332	.	_

Text=For patients vs. healthy controls comparison we computed the Bonferroni correction based on the number of variables in the cortex and subcortical regions separately because published literature values have been reported for single structures and single hemispheres, typically in separate reports.
70-1	12333-12336	For	_
70-2	12337-12345	patients	_
70-3	12346-12349	vs.	_
70-4	12350-12357	healthy	_
70-5	12358-12366	controls	_
70-6	12367-12377	comparison	_
70-7	12378-12380	we	_
70-8	12381-12389	computed	_
70-9	12390-12393	the	_
70-10	12394-12404	Bonferroni	_
70-11	12405-12415	correction	_
70-12	12416-12421	based	_
70-13	12422-12424	on	_
70-14	12425-12428	the	_
70-15	12429-12435	number	_
70-16	12436-12438	of	_
70-17	12439-12448	variables	_
70-18	12449-12451	in	_
70-19	12452-12455	the	_
70-20	12456-12462	cortex	_
70-21	12463-12466	and	_
70-22	12467-12478	subcortical	_
70-23	12479-12486	regions	_
70-24	12487-12497	separately	_
70-25	12498-12505	because	_
70-26	12506-12515	published	_
70-27	12516-12526	literature	_
70-28	12527-12533	values	_
70-29	12534-12538	have	_
70-30	12539-12543	been	_
70-31	12544-12552	reported	_
70-32	12553-12556	for	_
70-33	12557-12563	single	_
70-34	12564-12574	structures	_
70-35	12575-12578	and	_
70-36	12579-12585	single	_
70-37	12586-12597	hemispheres	_
70-38	12598-12599	,	_
70-39	12600-12609	typically	_
70-40	12610-12612	in	_
70-41	12613-12621	separate	_
70-42	12622-12629	reports	_
70-43	12630-12631	.	_

Text=An alternative was to compute the denominator based on the three-group comparison and the three two-group comparisons (variables×4).
71-1	12632-12634	An	_
71-2	12635-12646	alternative	_
71-3	12647-12650	was	_
71-4	12651-12653	to	_
71-5	12654-12661	compute	_
71-6	12662-12665	the	_
71-7	12666-12677	denominator	_
71-8	12678-12683	based	_
71-9	12684-12686	on	_
71-10	12687-12690	the	_
71-11	12691-12702	three-group	_
71-12	12703-12713	comparison	_
71-13	12714-12717	and	_
71-14	12718-12721	the	_
71-15	12722-12727	three	_
71-16	12728-12737	two-group	_
71-17	12738-12749	comparisons	_
71-18	12750-12751	(	_
71-19	12752-12763	variables×4	_
71-20	12764-12765	)	_
71-21	12766-12767	.	_

Text=However, this strategy could have been considered spuriously conservative since it would be associated with a false failure to replicate published findings.
72-1	12768-12775	However	_
72-2	12776-12777	,	_
72-3	12778-12782	this	_
72-4	12783-12791	strategy	_
72-5	12792-12797	could	_
72-6	12798-12802	have	_
72-7	12803-12807	been	_
72-8	12808-12818	considered	_
72-9	12819-12829	spuriously	_
72-10	12830-12842	conservative	_
72-11	12843-12848	since	_
72-12	12849-12851	it	_
72-13	12852-12857	would	_
72-14	12858-12860	be	_
72-15	12861-12871	associated	_
72-16	12872-12876	with	_
72-17	12877-12878	a	_
72-18	12879-12884	false	_
72-19	12885-12892	failure	_
72-20	12893-12895	to	_
72-21	12896-12905	replicate	_
72-22	12906-12915	published	_
72-23	12916-12924	findings	_
72-24	12925-12926	.	_

Text=Therefore, we present all data both as p <0.05 as replication and Bonferroni corrected for multiple structures.
73-1	12927-12936	Therefore	_
73-2	12937-12938	,	_
73-3	12939-12941	we	_
73-4	12942-12949	present	_
73-5	12950-12953	all	_
73-6	12954-12958	data	_
73-7	12959-12963	both	_
73-8	12964-12966	as	_
73-9	12967-12968	p	_
73-10	12969-12970	<	_
73-11	12971-12975	0.05	_
73-12	12976-12978	as	_
73-13	12979-12990	replication	_
73-14	12991-12994	and	_
73-15	12995-13005	Bonferroni	_
73-16	13006-13015	corrected	_
73-17	13016-13019	for	_
73-18	13020-13028	multiple	_
73-19	13029-13039	structures	_
73-20	13040-13041	.	_

